alexa Drug Therapy Impact Factor|OMICS International|Translational Medicine

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Drug Therapy Impact Factor

Impact Factor is a population statistic that reflects how many citations of a journal’s papers published over a two-year period receive during the subsequent year. “The annual Journal Citation Reports impact factor is a ratio between citations and recent citable items published: a journal’s impact factor is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years. Medical Journals provide a podium for unresolved research around the globe in the field of medicine. Medical journals contribute for the advancement and development of the scientific discoveries. Medical journals publish papers which provide information on diagnosis, treatment & prevention of various diseases. OMICS group medical journals papers publishing over 13000 articles every year, accessible to more than 100000 scholars throughout the world. With the support of more than 1000+ Scientific associations OMICS is a leading scientific event organizer, organizing 3000+ International Scientific Conferences all over the globe. The axial spondyloarthritides (axial SpA) are a related group of disorders prototypically represented by Ankylosing Spondylitis.Reactive arthritis, psoriatic arthritis, enteropathic arthritis and undifferentiated spondyloarthritis are also included in this family. The prevalence of this group of disorders roughly approximates that of ankylosing spondylitis, affecting 1% of the population.The experience of sulfasalazine in axial SpA is similar to methotrexate; it is not recommended in the most recent ASAS guidelines for axial disease. Sulfasalazine is an important drug for peripheral manifestations, however, and is recommended before a trial of TNF antagonists when NSAIDs have failed.The treatment of axial spondyloarthritis is evolving with the release of new consensus guidelines occurring every few years. Implementation of ASAS guidelines in clinical practice is ongoing. Recommendations for drug therapy are made largely in the context of ankylosing spondylitis, simultaneously a subtype and prototypical form of axial spondyloarthritis. Distinctions in the management of axial and peripheral arthritis are made based on the differential performance of medications used in clinical trials of ankylosing spondylitis patients. (Michael P. Keith,Overview of Drug Therapy for Spondyloarthritis)
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on July, 2014